<DOC>
	<DOCNO>NCT01118130</DOCNO>
	<brief_summary>To investigate whether genotypic difference identify MS patient develop 'liver injury ' ( define ALT level five time upper normal limit ) compare develop liver injury exposure beta-interferon MS .</brief_summary>
	<brief_title>Pharmacogenomics Drug Safety Multiple Sclerosis</brief_title>
	<detailed_description>PURPOSE : To investigate whether genotypic difference identify MS patient develop liver injury compare develop injury response beta-interferon therapy . OBJECTIVE : To determine whether elevated liver enzyme test ( ALT &gt; 5 time upper limit normal ) response beta-interferon therapy MS patient associate genetic polymorphism . METHOD OF RECRUITMENT : Patients identify clinic database chart review . An introductory letter mail potential participant , invite volunteer . A follow-up phone call make determine interest consent study . PROCEDURES : Saliva collect genetic analysis questionnaire administer</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Cases control must definite MS ( Poser McDonald criterion ) relapsingremitting secondaryprogressive disease course Prescribed betainterferon immunomodulatory drug MS primaryprogressive MS elevate liver test result within 6 month start betainterferon treatment presence comorbidity know riskfactor liver injury</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Genetics</keyword>
	<keyword>genomics</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>beta-interferon</keyword>
</DOC>